Skip to main content

Table 1 Clinical and demographic characteristics of the patients enrolled in the study

From: Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis

Case Age (years) Sex Duration (mo) MRSS baseline Organ involvement Previous treatments Maintain treatments Infectious AE
1 26 M 17 26   P 15 mg/d + MTX 10 mg/w P 5 mg/d + MTX 10 mg/w Minor respiratory tract infection
2 21 F 24 23   P10mg/d + penicillamine 0.375/d No treatment  
3 25 M 6 19   no treatment No treatment  
4 35 F 30 17   P 5 mg/d + penicillamine 0.375/d No treatment  
5 28 F 84 21 ILD acral ulcers P 20 mg/d + CTX 0.4/2 w P 10 mg/d + CTX 0.6/2 mo Minor respiratory tract infection
6 43 F 60 20   Penicillamine 0.375/d No treatment  
7 19 F 36 19   P 10 mg/d + AZA100 mg/d P 5 mg/d + AZA50 mg/d Minor respiratory tract infection
8 56 M 40 15 ILD P 15 mg/d CTX 0.4/2 w P 5 mg/d CTX 0.4/mo Minor respiratory tract infection
9 46 F 7 21   P 10 mg/d + GTW GTW  
10 30 F 42 18   P10mg/d + MMF 0.75 BID No treatment Minor respiratory tract infection
11 38 F 12 20 ILD dysphagia P 20 mg/d + CTX 0.1 QD + GTW P10mg + CTX 0.4/2 w + GTW  
12 67 F 6 25   P 10 mg/d + AZA 100 mg/d P 5 mg/d + AZA 50 mg/d Diarrhea
13 53 F 6 17   P 5 mg/d + MMF 0.75 BID P 5 mg/d  
14 36 F 6 21   No treatment No treatment  
  1. Duration was from the first symptom of disease to the time receiving plasmapheresis (PE) + mesenchymal stem cell transplantation (MSCT). Skin MRSS modified Rodnan skin score, AE adverse events, ILD interstitial lung disease, P prednisone, CTX cyclophasphomide, MTX methotrexate, AZA azathioprine, GTW glycosides of Tripterygium wilfordi, MMF mycophenolate mofetil, BID twice daily